Literature DB >> 10607727

Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate.

F Chai1, A Evdokiou, G P Young, P D Zalewski.   

Abstract

Butyrate, a short chain fatty acid produced in the colon, induces apoptosis in cancer cell lines by a sequential process involving inhibition of histone deacetylase, de novo protein synthesis and activation of DEVD-caspase, a major effector of apoptotic DNA fragmentation and membrane blebbing. We now show, in LIM 1215 colorectal cancer cells, that butyrate, in addition to activating DEVD-caspase and inducing apoptosis, also increases expression and cleavage of the universal cyclin-dependent kinase inhibitor p21(Waf1/Cip1) and leads to hypo-phosphorylation of retinoblastoma protein. Accompanying these molecular changes was a progressive loss of G(0)/G(1) and S phase cells. Expression of p21 had similar kinetics to that of the essential protein required for DEVD-caspase activation, indicating parallel effects of butyrate on anti-apoptotic and pro-apoptotic mechanisms. LIM 1215 cells, which were resistant to butyrate-induced apoptosis, were selected by three cycles of exposure to butyrate and removal of floating apoptotic cells. These cells showed markedly enhanced p21 expression and were in cell cycle arrest as determined by flow cytometry. On the other hand, subsequent culture of these cells for 2-3 days in the absence of butyrate resulted in down-regulation of p21 and restoration of sensitivity to apoptosis by butyrate. Western blots of butyrate-treated cells undergoing apoptosis consistently demonstrated a 15 kDa band (p15) that was not present in control cultures. This band became apparent immediately after the onset of DEVD-caspase activation, was enriched in the floating apoptotic cell population when compared with the adherent, non-apoptotic cells and was absent in butyrate-resistant cells lacking DEVD-caspase activity. Peptide caspase inhibitors partially blocked appearance of p15. Here we show, for the first time, that p21 is a target of effector caspases in colorectal cancer cells and that the resistance to butyrate-induced apoptosis is characterized by failure of p21 cleavage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10607727     DOI: 10.1093/carcin/21.1.7

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  15 in total

1.  Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells.

Authors:  Jacinta Serpa; Francisco Caiado; Tânia Carvalho; Cheila Torre; Luís G Gonçalves; Cristina Casalou; Pedro Lamosa; Margarida Rodrigues; Zhenping Zhu; Eric W F Lam; Sérgio Dias
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

2.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Authors:  Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275.

Authors:  Annette Altmann; Michael Eisenhut; Ulrike Bauder-Wüst; Annette Markert; Vasileios Askoxylakis; Holger Hess-Stumpp; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-03       Impact factor: 9.236

4.  Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related.

Authors:  Kevin M Beggs; Ashley R Maiuri; Aaron M Fullerton; Kyle L Poulsen; Anna B Breier; Patricia E Ganey; Robert A Roth
Journal:  Toxicology       Date:  2015-03-05       Impact factor: 4.221

5.  Targeted destruction of DNA replication protein Cdc6 by cell death pathways in mammals and yeast.

Authors:  Frederic Blanchard; Michael E Rusiniak; Karuna Sharma; Xiaolei Sun; Ivan Todorov; M Mar Castellano; Crisanto Gutierrez; Heinz Baumann; William C Burhans
Journal:  Mol Biol Cell       Date:  2002-05       Impact factor: 4.138

6.  Upregulation of p21Waf1/Cip1 expression in vivo by butyrate administration can be chemoprotective or chemopromotive depending on the lipid component of the diet.

Authors:  Kristy Covert Crim; Lisa M Sanders; Mee Young Hong; Stella S Taddeo; Nancy D Turner; Robert S Chapkin; Joanne R Lupton
Journal:  Carcinogenesis       Date:  2008-06-20       Impact factor: 4.944

7.  FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus.

Authors:  Runhua Liu; Lizhong Wang; Guoyun Chen; Hiroto Katoh; Chong Chen; Yang Liu; Pan Zheng
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

8.  PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.

Authors:  Savita Bhalla; Sriram Balasubramanian; Kevin David; Mint Sirisawad; Joseph Buggy; Lauren Mauro; Sheila Prachand; Richard Miller; Leo I Gordon; Andrew M Evens
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

9.  Influence of miRNA-106b and miRNA-135a on butyrate-regulated expression of p21 and Cyclin D2 in human colon adenoma cells.

Authors:  W Schlörmann; S Naumann; C Renner; M Glei
Journal:  Genes Nutr       Date:  2015-11-12       Impact factor: 5.523

10.  L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro.

Authors:  Hongbiao Huang; Ningning Liu; Haiping Guo; Siyan Liao; Xiaofen Li; Changshan Yang; Shouting Liu; Wenbin Song; Chunjiao Liu; Lixia Guan; Bing Li; Li Xu; Change Zhang; Xuejun Wang; Q Ping Dou; Jinbao Liu
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.